By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel is divided on whether Philip Morris International (PM) or Altria (MO) is the better long-term investment in the smoke-free transition. While PM has a significant lead in smoke-free products, its international exposure to regulatory risks and currency fluctuations is a concern. MO, on the other hand, has pricing power and a strong dividend, but its reliance on the U.S. market and potential challenges with the Master Settlement Agreement pose risks.
Risk: Accelerated smoke-free adoption leading to faster cigarette volume declines and margin compression.
Opportunity: PM's lead in smoke-free products and expansion into the U.S. market.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Key Points
Cigarettes are a remarkably resilient business, but it won't last forever.
Philip Morris began developing smoke-free products much earlier, and it shows in the financials.
Altria's dependence on Marlboro cigarettes will remain a red flag for the foreseeable future.
- 10 stocks we like better than Altria Group ›
There hasn't been, and may never be, a more resilient industry than tobacco. Despite smoking rates in the United States peaking many decades ago, the top tobacco stocks are still megacap behemoths that pay and raise shareholder dividends each year. Among them are Altria Group (NYSE: MO) and Philip Morris International (NYSE: PM), former sister companies that sell Marlboro cigarettes in the United States and internationally.
The companies have diverged significantly since separating in 2008. Today, emerging smoke-free nicotine products, from oral pouches to vapes, have breathed new life into the industry.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
But which tobacco giant is the better stock to buy and hold forever?
Smoke-free products will become increasingly important
Cigarettes are a unique product due to their addictive properties and the industry's high regulatory barriers. Altria has managed to continuously offset declining cigarette volumes with price increases, eking out modest growth to fund dividend increases. The company is a Dividend King, with more than 50 years of uninterrupted dividend growth.
Philip Morris has enjoyed a large, but lower-margin, international market. One major difference is that it chose to aggressively pursue new products. Philip Morris launched a heated tobacco brand, Iqos, more than a decade ago and acquired Swedish Match, the maker of the leading nicotine salt pouch brand Zyn, in 2022.
Smoke-free products now account for 41.5% of Philip Morris's total net sales, while Altria still relies almost entirely on smokable products.
What makes Philip Morris the winner
Altria's legacy Marlboro brand is resilient to almost the point of embarrassment, so investors shouldn't panic yet. The company still has time to establish itself in the smoke-free space. That said, it still must prove it can do it. Altria failed miserably with its Juul investment, and its On! nicotine pouch brand lags Zyn in the U.S. market.
Meanwhile, Philip Morris has a years-long track record of ramping up Iqos in international markets and is rolling it out in the United States. Zyn has faced competition, but remains the industry leader and is growing by leaps and bounds as the broader market for oral nicotine pouches continues to soar.
If Altria doesn't make meaningful progress in the next few years with a cigarette alternative, such as a heated tobacco or vaping device, Iqos and other smoke-free products could really start to pressure its cigarette business. If volume declines accelerate, they could quickly turn Altria's business on its head.
Right now, Philip Morris has clear competitive advantages in the smoke-free arena, which positions it well for the long term. Until Altria Group can deliver tangible results outside its core business, it's a no-brainer for investors to buy and hold Philip Morris.
Should you buy stock in Altria Group right now?
Before you buy stock in Altria Group, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Altria Group wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $495,179!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,058,743!*
Now, it’s worth noting Stock Advisor’s total average return is 898% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of March 24, 2026.
Justin Pope has positions in Philip Morris International. The Motley Fool recommends Philip Morris International. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"PM's product diversification advantage is real, but the article underweights regulatory risk to smoke-free products and assumes MO's pricing power will collapse faster than historical precedent suggests."
The article's PM-over-MO thesis rests on a plausible but incomplete premise: that smoke-free products will cannibalize cigarettes faster than MO can adapt. True, PM's 41.5% smoke-free mix beats MO's near-zero. But MO's Marlboro pricing power is genuinely formidable—it's offset volume declines for decades. The real risk isn't whether PM is ahead; it's whether either company's smoke-free growth can offset cigarette margin collapse. PM's Zyn is growing, but oral pouches face their own regulatory headwinds (FDA restrictions, state bans). Neither company has solved the fundamental problem: shrinking TAM.
MO's dividend aristocrat status and Marlboro's pricing moat mean it could milk cash for 10+ years while competitors fight over a shrinking pie—potentially outperforming PM on total return if PM's smoke-free bets disappoint or face regulatory setbacks.
"Philip Morris is no longer just an international play; it is a direct domestic threat to Altria's U.S. dominance via Zyn and IQOS."
The article correctly identifies Philip Morris International (PM) as the structural winner in the smoke-free transition, but it ignores the valuation and yield gap. Altria (MO) currently trades at a significant discount—roughly 8-9x forward P/E compared to PM’s 15-17x—while offering a dividend yield near 8.5%. The 'red flag' of Marlboro dependency is priced in. The real story is PM's U.S. expansion; by acquiring Swedish Match (Zyn) and regaining U.S. rights to IQOS, PM is now a direct competitor on MO's home turf. MO isn't just fighting a declining market; it's fighting a better-capitalized innovator in its only profitable geography.
If the FDA implements a menthol ban or nicotine ceiling, MO's domestic concentration becomes a terminal liability, whereas PM's geographic diversification acts as a built-in insurance policy against any single nation's regulatory whims.
"PM’s smoke-free leadership gives it a strategic advantage, but regulatory, integration, and valuation risks mean neither company is a no-brainer "buy and hold forever" without close monitoring of product adoption and policy outcomes."
The headline conclusion — Philip Morris (PM) is the safer "forever" pick because it moved earlier into smoke-free products — is directionally correct but incomplete. PM’s leadership in IQOS and the Zyn acquisition give it optionality if regulators and consumers shift toward reduced-risk products, yet execution, integration costs, FX exposure, and potential margin compression aren’t discussed. Altria (MO), meanwhile, still generates huge, stable U.S. cash flows, has pricing power, and a massive dividend that matters to income investors. "Buy and hold forever" depends less on current product roadmaps than on regulatory outcomes, litigation risk, and each firm’s ability to redeploy cash into durable, higher-margin alternatives.
If regulators continue to accept reduced-risk claims and consumer uptake of IQOS/Zyn keeps accelerating globally, PM could materially outgrow MO and re-rate higher, making PM the obvious long-term winner. Conversely, a regulatory or litigation shock against nicotine pouches or heated products could level the playing field back toward Altria’s cash-rich cigarette business.
"Altria's U.S. pricing moat and unmatched dividend history outweigh PM's smoke-free lead for a true 'buy and hold forever' in tobacco."
The article pushes PM as the clear winner due to its 41.5% smoke-free sales from Iqos and Zyn, versus MO's near-total cigarette reliance and past Juul flop. But it omits key context: Altria's 2023 NJOY vape acquisition (FDA-authorized) and On! pouch growth, plus Marlboro's ~42% U.S. share enabling 7-10% annual pricing hikes to offset 5-8% volume drops (historical trend). MO's Dividend King status (55+ years raises) delivers ~8-9% yield versus PM's ~5%, with U.S.-only focus dodging PM's FX and international reg volatility. For 'forever' hold, MO's FCF machine endures longer than PM's unproven U.S. ramp.
PM's decade-long Iqos execution and Zyn market leadership (post-Swedish Match buy) could explode in the U.S., pressuring MO's volumes if smoke-free adoption surges amid declining cig loyalty.
"MO's pricing moat masks a volume cliff risk that accelerates if smoke-free adoption inflects upward—Zyn's market dominance makes that inflection PM's to trigger."
Grok flags MO's NJOY and On! growth, but those are niche relative to PM's Zyn dominance—Zyn owns ~70% U.S. oral pouch market. The real gap: MO's pricing power works only if volume declines stay gradual. If smoke-free adoption accelerates (plausible given younger cohorts), Marlboro's 42% share doesn't protect unit economics. Grok's 'FCF machine endures longer' assumes cigarette TAM shrinks predictably. It won't. Discontinuities kill cash flows faster than steady margin compression.
"Altria's pricing power is a finite strategy that cannot indefinitely offset the compounding pressure of U.S. regulatory concentration and MSA payment structures."
Grok's defense of Altria's pricing power ignores a looming fiscal cliff: the Master Settlement Agreement (MSA). As MO raises prices to offset volume drops, it hits a ceiling where state excise taxes and MSA payments—linked to volume—become disproportionately burdensome on remaining smokers. PM’s international footprint allows it to absorb regulatory shocks in one region with growth in another. MO is trapped in a single, increasingly hostile regulatory jurisdiction with no geographical hedge.
"Altria’s large dividend is materially exposed if cigarette revenues decline faster or smoke‑free margins underperform, risking payout cuts."
Gemini focuses on MO’s cheap P/E and huge yield but misses dividend sustainability risk: Altria’s payout is heavily dependent on high-margin U.S. cigarette cash flow. If smoke‑free adoption accelerates or MO’s smoke‑free margins trail PM’s, Altria’s payout ratio could rise materially, forcing dividend cuts or curtailed buybacks. This isn’t hypothetical—MO’s geographic concentration removes a diversification buffer that PM benefits from (speculation labeled).
"Altria's MSA prepayments neutralize the volume-linked fiscal cliff, bolstering cash flow predictability over PM's regulatory dispersion."
Gemini's MSA 'fiscal cliff' overlooks Altria's strategic gross settlements: since 2020, MO prepaid $9B+ in MSA obligations, converting variable volume-linked payments to fixed, shielding against further volume drops. This fortifies dividend sustainability (2023 FCF $8.1B covers $6.5B payout + buybacks). PM faces symmetric risks from EU pouch regs, no free lunch on 'diversification'.
The panel is divided on whether Philip Morris International (PM) or Altria (MO) is the better long-term investment in the smoke-free transition. While PM has a significant lead in smoke-free products, its international exposure to regulatory risks and currency fluctuations is a concern. MO, on the other hand, has pricing power and a strong dividend, but its reliance on the U.S. market and potential challenges with the Master Settlement Agreement pose risks.
PM's lead in smoke-free products and expansion into the U.S. market.
Accelerated smoke-free adoption leading to faster cigarette volume declines and margin compression.